Cognition Therapeutics Inc (CGTX)

$CGTX last chance to load up.

$CGTX Welp.. Let's see

$CGTX From my swing thing list👍

$CGTX nice week. Could be a good afternoon as well

$CGTX my nemesis

$CGTX Blocked all avxl and anvs pumpers and spammers

$AVXL investors such as @kitty7kitty, @Trainguy1, and of course most importantly Mayo/Jesse, have provided great conversations with me through the years. The due diligence (dd) has been great, albeit too often wholly towards the positive. This is a common pitfall when stock channels isolated themselves to ONLY one stock. Nearly every positive Anavex ideal can be and/or has already been applied to Annovis. Anavex investors sometimes come up with great ideas, but forget that same idea could applied to any other company ... including 💩 ones! The fact is that experienced and well run biotech companies are grounded in proven industry routes to success (i.e. $COYA) ... not through unusual routes such as misleading investors with nearly non-existent pipelines. An example of this has been Anavex's practice of including as many as seven (7) "planned trials" in their pipeline graphics using colors that casual observers tell me "I didn't know 7 of them weren't real" or something like this. Sample: https://dd4us.weebly.com/uploads/1/0/3/3/10336302/screenshot_2024-02-18_at_10.22.19_pm.png Investors make their decisions based on large part from the information provided by the CEO and the company. I know several attorneys who invested 1M or more into Annovis Bio such as @ReturnOfEsquire These are smart attorneys. Attorneys read everything! The average investor cannot come close to passing the bar exam which is extremely difficult and is considered one of the most challenging professional exams in the US. Attorneys miss very little. But, no attorney would assume that a CEO would bend SEC regulations and lie so blatantly to retail investors. IMO, this is how a group of investors, such as those on this channel can harness their collective observations and hold CEOs to their word. Image 1: Was a calendar I offered to this group back in 2023 to track CEO Missling's corporate promises. Unfortunately, no one was interested. Image 2: I collaborated with Trainguy1 to collate the 2023 Rett Year-End AVXL poll. Unfortunately, the outcome on the first trading day of the year was a -10x delta from this 2023 poll's median. The average predicted $45.54 figure was even worst. I know that Trainguy1 had offered to conduct another poll for the recent Alzheimer's app which most likely would have resulted in a similar outcome. IMO, it is through comparative analysis where value is measured. In general, most assets are assessed comparatively. Typically, when I post on this channel someone will reply with a "This is an AVXL only channel" and that posts ends up with 20+ likes. On this occasion I sincerely hope that readers will consider the request in the paragraph that follows. ANVS should NOT be a public traded company and you can help with a simple "like". Thank you 🙏 IMO, ANVS is a threat to AVXL and all other biotech companies in this space. If the information in this post has been helpful, please like this post so that it can populate the ANVS feed more prominently: 👉 https://stocktwits.com/ForestFoxes/message/651170548 Copying in $COYA (my biggest holding currently in this space for its strength of management) $CGTX and $ANNX because they are peers in this space and appear better connected and better operated than the problems that are in other companies in this arena.

$AVXL investors are optimists, which I appreciate ☺️ When hoping for a deal with a foreign country or countries one should consider that CEOs without scruples will brag that, "A country in Europe or a country in the whatever. OK, I can't be too specific. So that is the low hanging fruit ...". According to the CEO of Annovis Bio getting partnerships is easy as taking candy from a baby ... or, is that money from patients, their families, and retail investors? IMO, ANVX is a threat to AVXL and all other biotech companies in this space. If the information in this post has been helpful, please like this post so that it can populate the ANVS feed more prominently: 👉 https://stocktwits.com/ForestFoxes/message/651170548 Thank you for reading and liking the requested post. Copying in $COYA (my biggest holding currently in this space for its strength of management) $CGTX and $ANNX because they are peers in this space and appear better connected and better operated than the problems that are in other companies in this arena.

$AVXL Right to Try (RTT) is unlikely to happen for various reasons. I know from an authoritative source that buntanetap from Annovis Bio who is one of Anavex's biggest competitors will never RTT their drug even if their CEO wanted to. Here's an FDA link to RTT: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try (Be sure to click the "FDA Right to Try Fact Sheet" in the link above) Image 1: Included to preserve the utility of this post since Stocktwits accounts may be to closed in the future and hence referenced/reshared posts disappear. Image 2: Some basic reasons why Anavex is highly unlikely to include RTT. Biotech companies are generally cautious about providing unapproved drugs, even though legal pathways like "Expanded Access" (compassionate use) and "Right to Try" exist. While companies may allow it, they are not required to do so and often refuse due to limited drug supply, safety concerns, potential interference with clinical trials, and liability risks. IMO, ANVX is a threat to AVXL and all other biotech companies in this space. If the information in this post has been helpful, please like this post so that it can populate the ANVS feed more prominently: 👉 https://stocktwits.com/ForestFoxes/message/651170548 Thank you for reading and liking the requested post. Copying in $COYA (my biggest holding currently in this space) $CGTX and $ANNX because they are peers in this space and appear better connected and better operated than the problems that are in other companies in this space.